AIM ImmunoTech Inc. (AIM)

↓ Download CSV

CIK 0000946644 · NYSE · Biological Products, (No Diagnostic Substances)

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

In fiscal 2025, AIM ImmunoTech Inc. reported revenue of $88.0K, down 48.2% from the prior year. The company ran a net loss, with a net margin of -15861.4%. It held $5.78M in total assets against $15.56M in total liabilities.

Key ratios (FY2025)

-13254.5%
Operating margin
-15861.4%
Net margin
-48.2%
Revenue growth (YoY)
Metric (FY)2025202420232022202120202019201820172016
Revenue$88.0K$170.0K$202.0K$141.0K$367.0K$437.0K
Operating Income-$11.66M-$19.77M-$31.92M-$19.92M-$18.84M-$15.15M-$12.44M-$11.50M-$11.42M-$13.80M
Net Income-$13.96M-$17.32M-$28.96M-$19.45M-$19.13M-$14.40M-$9.40M-$9.83M-$8.26M-$7.50M
EPS (Diluted)$-8.62$-30.92$-0.60$-0.40$-0.40
Total Assets$5.78M$8.61M$19.38M$40.49M$57.70M$64.58M$20.75M$13.85M$14.21M$18.87M
Total Liabilities$15.56M$9.93M$9.15M$2.02M
Shareholders' Equity-$9.78M-$1.32M$10.23M$38.47M$56.88M$61.29M$13.44M$5.58M$8.70M$15.50M
Cash & Equivalents$2.98M$1.70M$5.44M$27.05M$32.09M$38.50M$1.47M$299.0K$1.41M$2.41M
Operating Cash Flow-$10.96M-$14.89M-$21.27M-$16.11M-$13.96M-$10.37M-$9.07M-$10.64M-$7.94M-$7.38M
Capital Expenditures$18.0K$86.0K$41.0K$22.0K$68.0K$51.0K$20.0K$160.0K
Shares Outstanding3.07M655.3K49.10M48.08M47.99M42.15M10.39M1.11M32.88M24.20M